Multiple Sclerosis Drugs - Morocco

Morocco

The Multiple Sclerosis Drugs market in Morocco is anticipated to witness a significant increase in revenue, with projections indicating a figure of US$11.61m in 2024.
Moreover, the market is expected to display a steady annual growth rate (CAGR 2024-2029) of 1.44%, leading to a market volume of US$12.47m by 2029.
When compared globally, United States is expected to generate the highest revenue, reaching a staggering US$11,770.00m in 2024.
Morocco's market for Multiple Sclerosis Drugs is witnessing a surge in demand due to increasing awareness and improved access to healthcare facilities.

Key regions: France, India, United Kingdom, South Korea, Japan

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Multiple Sclerosis Drugs in Morocco has been increasing steadily in recent years.

Customer preferences: Patients suffering from Multiple Sclerosis in Morocco prefer to use drugs that have been approved by the Moroccan Ministry of Health. They are also more inclined towards drugs that have fewer side effects and are more affordable. Patients in Morocco also prefer to use drugs that are easily available at local pharmacies.

Trends in the market: The Multiple Sclerosis Drugs market in Morocco has been growing due to the increasing number of patients suffering from the disease. The market has also been driven by the introduction of new drugs that are more effective in treating the disease. The market has also seen an increase in the number of generic drugs that are more affordable and easily accessible to patients.

Local special circumstances: Morocco has a high prevalence of Multiple Sclerosis among the North African countries. The disease is more common in women than in men. The country has a limited number of neurologists, which makes it difficult for patients to access specialized care. The Moroccan government has taken steps to improve access to healthcare by increasing the number of hospitals and clinics in the country.

Underlying macroeconomic factors: The Moroccan economy has been growing steadily in recent years, which has led to an increase in healthcare spending. The government has been investing in healthcare infrastructure and has been working to improve access to healthcare services. The growth of the pharmaceutical industry in Morocco has also contributed to the growth of the Multiple Sclerosis Drugs market. The pharmaceutical industry in Morocco has been expanding due to the country's strategic location, favorable business environment, and the availability of skilled labor.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.